Skip to main content
Lawrence Wiesner, DO, Orthopaedic Surgery, Binghamton, NY

LawrenceWiesnerDO

Orthopaedic Surgery Binghamton, NY

Hip & Knee Reconstructive Surgery

Director of Orthopedic Surgery

Dr. Wiesner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Wiesner's full profile

Already have an account?

  • Office

    33 Mitchell Ave
    Suite G50
    Binghamton, NY 13903
    Phone+1 607-771-2220
    Fax+1 607-771-2225

Education & Training

  • Peninsula Hospital Center
    Peninsula Hospital CenterResidency, Orthopaedic Surgery, 1996 - 2001
  • Lutheran Medical Center
    Lutheran Medical CenterInternship, Transitional Year, 1995 - 1996
  • NYIT College Of Osteopathic Medicine
    NYIT College Of Osteopathic MedicineClass of 1995

Certifications & Licensure

  • NY State Medical License
    NY State License 1999 - 2025
  • FL State Medical License
    FL State License 2000 - 2024
  • AOA Board of Orthopedic Surgery Orthopedic Surgery

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013

Press Mentions

  • AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery
    AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement SurgeryJanuary 12th, 2022
  • AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery
    AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement SurgeryDecember 15th, 2021
  • AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery
    AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement SurgeryDecember 15th, 2021

Professional Memberships